Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOURCE Syndax Pharmaceuticals, Inc.WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on January 1, 2025 the Company granted inducement awards to purchase up to 123,100 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
美国马萨诸塞州沃尔瑟姆，2025年1月3日 /PRNewswire/ -- Syndax Pharmaceuticals（纳斯达克：SNDX）是一家商业阶段的生物制药公司，正在开发一系列创新的癌症治疗方案。公司今天宣布，2025年1月1日，向五名新员工授予购买最多123,100股普通股的激励奖励，依据公司的2023年激励计划。这些股票期权将在四年内逐步生效，基础股份的25%将在生效开始日期的一周年纪念日生效，之后每月生效1/48的基础股份，持续36个月，前提是员工在相关生效日期期间与Syndax保持持续的服务关系。
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X and LinkedIn.
关于Syndax
Syndax Pharmaceuticals是一家商业阶段的生物制药公司，正在开发一系列创新的癌症治疗方案。公司的管线亮点包括Revuforj（revumenib），一款FDA批准的menin抑制剂，以及Niktimvo（axatilimab-csfr），一款FDA批准的单克隆抗体，阻断集落刺激因子1（CSF-1）受体。Syndax致力于重新构想癌症护理，努力发掘其管线的全部潜力，并在整个治疗过程的多个临床试验中进行探索。欲了解更多信息，请访问或在X和LinkedIn上关注公司。
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827
Syndax联系信息
香农·克拉赫
Syndax Pharmaceuticals, Inc.
[email protected]
电话 781.684.9827
SOURCE Syndax Pharmaceuticals, Inc.
来源 Syndax Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想让贵公司的资讯在PRNEWSWIRE.COM上特色展示吗？
